Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 5/20 | 0.42 |
| ▸ | CTSL | P07711 | 3/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4051480 | 1.00 | CTSK (0.46) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL4172764 | 0.81 | CA1 (0.45) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL8220897 | 0.80 | CA1 (0.46) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL16810043 | 0.80 | CTSK (0.50) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL29168072 | 0.80 | CA1 (0.46) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL23849248 | 0.75 | CA1 (0.52) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL148099 | 0.75 | CA1 (0.52) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL1371004 | 0.75 | CA1 (0.52) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL1369240 | 0.75 | CA1 (0.52) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL1563568 | 0.75 | CA1 (0.52) | CTSKCA1CA2CA7CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230138851-A1 | NOVEL ALKYNE DERIVATIVES | CARNA BIOSCIENCES, INC. (JP) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230138851-A1 | NOVEL ALKYNE DERIVATIVES | DYRK1B, DYRK3, DYRK2 | CTSK 378/4885CA1 4322/4885CA2 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.